Impact of Clinicopathologic Factors in Breast Cancer Treatment
Author Information
Author(s): Keam Bhumsuk, Im Seock-Ah, Kim Hee-Jun, Oh Do-Youn, Kim Jee Hyun, Lee Se-Hoon, Chie Eui Kyu, Han Wonshik, Kim Dong-Wan, Moon Woo Kyung, Kim Tae-You, Park In Ae, Noh Dong-Young, Heo Dae Seog, Ha Sung Whan, Bang Yung-Jue
Primary Institution: Seoul National University College of Medicine
Hypothesis
What are the predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy?
Conclusion
Triple negative breast cancer patients showed a higher response rate to chemotherapy but had shorter survival compared to non-triple negative patients.
Supporting Evidence
- Patients with triple negative phenotype showed higher response rates to chemotherapy.
- Relapse free survival and overall survival were significantly shorter in triple negative breast cancer patients.
- Initial clinical stage was the only significant independent prognostic factor impacting overall survival.
Takeaway
This study looked at breast cancer patients who received special chemotherapy and found that those with a certain type of cancer (triple negative) responded well to treatment but didn't live as long.
Methodology
145 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin chemotherapy, and clinical outcomes were analyzed in relation to various clinicopathologic parameters.
Limitations
The study had a relatively short follow-up period of 18.6 months, which may limit the understanding of long-term outcomes.
Participant Demographics
Median age of participants was 45 years, with a range from 25 to 69 years; most were clinical stage III at diagnosis.
Statistical Information
P-Value
p = 0.012
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website